title: Quantitative synthesis of the association between the cytochrome P450 1A1 Ile462Val polymorphism and prostate cancer risk.
abstract: The association between the cytochrome P450 1A1 (CYP1A1) Ile462Val polymorphism and prostate cancer risk remains inconclusive owing to the conflicting findings from previous studies. To get a more precise estimate of the possible association, we performed the present meta-analysis. We searched the PUBMED, EMBASE, and Wanfang databases for the studies which met the inclusion criteria. The pooled odds ratio (OR) with corresponding 95 % confidence interval (95 % CI) was used to estimate the association between CYP1A1 Ile462Val polymorphism and prostate cancer risk. A total of 13 studies with 2,350 cases and 2,992 controls were included in the meta-analysis. The results indicated that there was an obvious association between CYP1A1 Ile462Val polymorphism and increased risk of prostate cancer (for Val versus Ile: OR=1.27, 95 % CI 1.13-1.43, P<0.001; for ValVal versus IleIle: OR=1.51, 95 % CI 1.14-2.01, P=0.004; for ValVal + ValIle versus IleIle: OR=1.31, 95 % CI 1.14-1.51, P<0.001; for ValVal versus IleIle + ValIle: OR=1.38, 95 % CI 1.05-1.81, P=0.020). Subgroup analyses by ethnicity suggested that CYP1A1 Ile462Val polymorphism was associated with prostate cancer risk in Asians but not in Caucasians. This meta-analysis suggests that there is an association between CYP1A1 Ile462Val polymorphism and increased risk of prostate cancer. More studies with large sample are needed to further assess the association in Caucasians.
authors: Urology Department, The First Affiliated Hospital of Xinxiang Medical University, Healthy Road No. 88, Weihui, Henan, 453100, China. guangyehan@163.com
authors: Guangye
authors: G
authors: Han
authors: Yanjuan
authors: Y
authors: Ma
authors: Pei
authors: P
authors: Liu
authors: Xiaoxia
authors: X
authors: Wei
authors: Xinjun
authors: X
authors: Zhang
authors: Feng
authors: F
authors: Zhu
mesh_terms: D016022:Case-Control Studies; D019363:Cytochrome P-450 CYP1A1 / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D011110:Polymorphism, Genetic / Q000235:genetics*; D011471:Prostatic Neoplasms / Q000209:etiology*; D012307:Risk Factors
chemical_list: D019363:Cytochrome P-450 CYP1A1
references: Stat Med. 2002 Jun 15;21(11):1539-58
references: 12111919
references: Tumour Biol. 2011 Dec;32(6):1209-15
references: 21870186
references: Crit Rev Oncol Hematol. 1993 Feb;14(1):77-87
references: 8103989
references: Cancer Genet Cytogenet. 2004 Oct 1;154(1):81-5
references: 15381379
references: Cancer Lett. 2003 Jun 10;195(2):177-83
references: 12767526
references: Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1869-80
references: 19505920
references: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references: 13655060
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Int J Urol. 2006 Jun;13(6):773-80
references: 16834659
references: Cancer Res. 2009 Mar 1;69(5):1877-84
references: 19223546
references: Prostate Cancer Prostatic Dis. 2002;5(1):22-7
references: 15195126
references: Zhonghua Wai Ke Za Zhi. 2005 Nov 15;43(22):1467-70
references: 16318816
references: Prostate. 2013 Jan;73(1):1-10
references: 22549291
references: Cancer Lett. 2001 Apr 26;165(2):171-7
references: 11275366
references: Eur J Epidemiol. 2005;20(1):79-88
references: 15756908
references: Pharmacogenetics. 1991 Nov;1(2):68-78
references: 1844873
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):165-8
references: 17220347
references: Int J Biochem. 1989;21(3):243-52
references: 2545475
references: Tumour Biol. 2011 Dec;32(6):1097-102
references: 21773856
references: Tumour Biol. 2012 Aug;33(4):967-78
references: 22252524
references: Lancet. 2008 May 17;371(9625):1710-21
references: 18486743
references: Zhonghua Nan Ke Xue. 2003 Feb;9(1):32-5
references: 12680328
references: CA Cancer J Clin. 2005 Sep-Oct;55(5):300-18; quiz 323-5
references: 16166075
references: Chemosphere. 2010 Sep;81(4):464-8
references: 20817259
references: Int J Cancer. 2003 Sep 1;106(3):375-8
references: 12845676
references: Chin Med J (Engl). 2008 Feb 20;121(4):305-8
references: 18304461
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: Nat Rev Genet. 2009 Feb;10(2):77-82
references: 19104501
references: Urol Oncol. 2011 Nov-Dec;29(6):654-63
references: 20884258
references: Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):756-61
references: 16614120
references: Asian J Androl. 2006 May;8(3):349-55
references: 16625286
references: Cancer Invest. 2006 Feb;24(1):41-5
references: 16466991
references: Nat Rev Cancer. 2010 Mar;10(3):205-12
references: 20147902
references: Tumour Biol. 2012 Dec;33(6):2265-72
references: 22948778
references: Genet Test Mol Biomarkers. 2012 Jul;16(7):661-6
references: 22304463
references: Drug Metab Dispos. 2012 Dec;40(12):2324-31
references: 22949628
references: BMC Cancer. 2009 Jun 16;9:187
references: 19531241
references: Expert Opin Drug Metab Toxicol. 2009 May;5(5):501-21
references: 19416086